{"id":"placebo-for-tanezumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Placebo effect (symptom improvement without active drug)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. In this context, it serves as the control arm in phase 3 trials of tanezumab, a nerve growth factor (NGF) inhibitor being developed for pain management. Any observed effects in placebo recipients are attributed to the placebo effect or natural disease progression.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:32.164Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in tanezumab phase 3 clinical trials for osteoarthritis pain"}]},"trialDetails":[{"nctId":"NCT00999518","phase":"PHASE2","title":"A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-01-22","conditions":"Cystitis, Interstitial","enrollment":205},{"nctId":"NCT00584870","phase":"PHASE2","title":"RN624 In Adult Patients With Chronic Low Back Pain","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-07-05","conditions":"Low Back Pain","enrollment":220},{"nctId":"NCT00876187","phase":"PHASE2","title":"A Study of Tanezumab in Adults With Chronic Low Back Pain","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06-15","conditions":"Low Back Pain","enrollment":1359},{"nctId":"NCT00809354","phase":"PHASE3","title":"Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-02-12","conditions":"Osteoarthritis, Arthritis","enrollment":2720},{"nctId":"NCT00545129","phase":"PHASE2","title":"A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-04-29","conditions":"Neoplasm Metastasis, Palliative Care","enrollment":59},{"nctId":"NCT00568321","phase":"PHASE2","title":"RN624 For Pain Of Post-Herpetic Neuralgia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-12-19","conditions":"Neuralgia, Postherpetic","enrollment":99},{"nctId":"NCT00863304","phase":"PHASE3","title":"Tanezumab in Osteoarthritis of the Hip or Knee (2)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06-09","conditions":"Osteoarthritis","enrollment":849},{"nctId":"NCT00830063","phase":"PHASE3","title":"Tanezumab In Osteoarthritis Of The Knee (2)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-05-05","conditions":"Arthritis, Osteoarthritis","enrollment":832},{"nctId":"NCT00826514","phase":"PHASE2","title":"An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-03-25","conditions":"Chronic Prostatitis With Chronic Pelvic Pain Syndrome","enrollment":62},{"nctId":"NCT00601484","phase":"PHASE2","title":"An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-03-17","conditions":"Cystitis, Interstitial","enrollment":65},{"nctId":"NCT02697773","phase":"PHASE3","title":"Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-01-21","conditions":"Osteoarthritis, Knee, Osteoarthritis, Hip","enrollment":698},{"nctId":"NCT00784693","phase":"PHASE2","title":"A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis","status":"TERMINATED","sponsor":"Pfizer","startDate":"2008-12-18","conditions":"Endometriosis","enrollment":48},{"nctId":"NCT00864097","phase":"PHASE3","title":"Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-08-11","conditions":"Osteoarthritis","enrollment":607},{"nctId":"NCT00960804","phase":"PHASE3","title":"Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-02-15","conditions":"Osteoarthritis","enrollment":21},{"nctId":"NCT00863772","phase":"PHASE3","title":"Tanezumab and Nerve Function In Arthritis Patients","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-05-18","conditions":"Osteoarthritis","enrollment":220},{"nctId":"NCT02725411","phase":"PHASE3","title":"Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-05-26","conditions":"Low Back Pain","enrollment":277},{"nctId":"NCT02528253","phase":"PHASE3","title":"A Phase 3 Study of Tanezumab for Chronic Low Back Pain","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-08-18","conditions":"Low Back Pain","enrollment":1832},{"nctId":"NCT02528188","phase":"PHASE3","title":"Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-07-21","conditions":"Chronic Pain, Osteoarthritis, Hip, Osteoarthritis, Knee","enrollment":3021}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":65,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for tanezumab","genericName":"Placebo for tanezumab","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in tanezumab phase 3 clinical trials for osteoarthritis pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}